Eliminating epidemic Group A meningococcal meningitis in Africa through a new vaccine.
about
Challenges and Opportunities While Developing a Group A Meningococcal Conjugate Vaccine Within a Product Development Partnership: A Manufacturer's Perspective From the Serum Institute of IndiaTechnical Development of a New Meningococcal Conjugate VaccineFrom Epidemic Meningitis Vaccines for Africa to the Meningitis Vaccine ProjectAmbiguous Capture: Collaborative Capitalism and the Meningitis Vaccine ProjectHousehold crowding, social mixing patterns and respiratory symptoms in seven countries of the African meningitis beltWhom and where are we not vaccinating? Coverage after the introduction of a new conjugate vaccine against group A meningococcus in Niger in 2010Development of a group A meningococcal conjugate vaccine, MenAfriVac(TM).Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data.Molecular characterization of invasive meningococcal isolates from countries in the African meningitis belt before introduction of a serogroup A conjugate vaccine.Persistent low carriage of serogroup A Neisseria meningitidis two years after mass vaccination with the meningococcal conjugate vaccine, MenAfriVac.Phenotypic and genotypic characterization of meningococcal carriage and disease isolates in Burkina Faso after mass vaccination with a serogroup a conjugate vaccine.An outbreak of pneumococcal meningitis among older children (≥5 years) and adults after the implementation of an infant vaccination programme with the 13-valent pneumococcal conjugate vaccine in Ghana.A Vaccine Meets Its Promise: Success in Controlling Epidemic Meningitis in Sub-Saharan AfricaActive Surveillance for Adverse Events After a Mass Vaccination Campaign With a Group A Meningococcal Conjugate Vaccine (PsA-TT) in MaliNeisseria meningitidis Group A IgG1 and IgG2 Subclass Immune Response in African Children Aged 12-23 Months Following Meningococcal VaccinationLessons Learned From Enhancing Vaccine Pharmacovigilance Activities During PsA-TT Introduction in African Countries, 2010-2013.Population-Level Persistence of Immunity 2 Years After the PsA-TT Mass-Vaccination Campaign in Mali.Carriage of Neisseria lactamica in 1- to 29-year-old people in Burkina Faso: epidemiology and molecular characterization.Self-enforcing regional vaccination agreements.Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): lessons from past programs and implications for the future.Advances with vaccination against Neisseria meningitidis.Linkages between observed, modeled Saharan dust loading and meningitis in Senegal during 2012 and 2013.Serogroup A meningococcal conjugate (PsA-TT) vaccine coverage and measles vaccine coverage in Burkina Faso--implications for introduction of PsA-TT into the Expanded Programme on Immunization.The capsule polymerase CslB of Neisseria meningitidis serogroup L catalyzes the synthesis of a complex trimeric repeating unit comprising glycosidic and phosphodiester linkages.Molecular cloning and functional characterization of components of the capsule biosynthesis complex of Neisseria meningitidis serogroup A: toward in vitro vaccine production.Conjugate vaccine introduction in the African meningitis belt: meeting surveillance objectives.Developmental strategy fora new Group A meningococcal conjugate vaccine (MenAfriVacR).Cost-effectiveness of expanding childhood routine immunization against Neisseria meningitidis serogroups C, W and Y with a quadrivalent conjugate vaccine in the African meningitis belt.Successful African introduction of a new Group A meningococcal conjugate vaccine: Future challenges and next steps.The ongoing challenge of meningococcal disease.A Review of Meningococcal Disease and Vaccination Recommendations for Travelers.Vaccination strategies for the prevention of meningococcal disease.Meningococcus serogroup C clonal complex ST-10217 outbreak in Zamfara State, Northern Nigeria
P2860
Q26778263-5AE32703-4F67-411D-AB93-95DDDCFB9A8CQ26778279-EA49AAA4-E260-4B6F-86A4-9E8AE0412D01Q26778284-6C2E6B5D-9929-4B18-BDE9-1E9FD836D7D9Q28598111-C5D424B2-628D-45E7-9713-C0D88ADFA96EQ33837062-CB8C9BE5-38DD-42C4-9BEA-D60E046B1FA5Q34140152-9A9B3BCF-7B26-4505-8569-EFC9D7DDF9AAQ34267478-6C6CE9E0-F830-4BBB-B007-31D9B8807527Q34346578-A2B0637D-3455-461F-AE35-111BBB24A3B0Q34430626-84CFDC93-E7D2-4A63-9A40-3792AC59A9ECQ34707962-EDD1811E-7F2B-4A8C-9B72-FF80D4681EB2Q34892719-266188ED-1EC9-4E6A-BF28-A01017C3E8B3Q36166629-E1F77B44-2E6B-472F-932C-06FFEDFCABADQ36264995-B472621F-5191-4D0A-9843-13EA82B82326Q36265001-48985799-290A-4549-984D-D9D295B24F4DQ36265012-420DB571-85CD-45A8-B3E4-6176A593680BQ36265065-50A6E25E-0A84-46D4-A187-B0733D25C2BDQ36265080-320AAEB7-187D-4B44-B820-662C3F79AEAFQ36414192-83DD6F7A-F7B2-45EE-838D-E49B793DB504Q36596168-168A7074-9FE5-4AF7-8275-465D800A7B36Q37514748-37612638-74B6-4A77-8BEE-38D5F5E9C961Q38040527-BE58BE3A-E2DD-4042-BE6D-425A1BE36CB9Q38971997-BC3E4024-A737-40BE-9B01-64EFC139AFE8Q39045024-81450946-AD01-4CBE-8120-C944EEBA8C16Q40628911-0CCA902B-4BCB-4E41-82C5-F99615FB083BQ41990978-5D673B47-4F07-4CB4-8E08-01C9ECA5DAA3Q42287903-544EC089-1C59-4490-A604-914085FEB1C3Q46758477-7B4930CF-A2C3-44C1-8774-3AE7699AE36FQ47135367-2FD3097B-C660-45C1-8281-3F38EDEB9757Q47920054-995722CB-BC38-4DDE-AD44-D139581E045EQ49344090-C74A9092-FF4C-4B18-9902-23FE09D3A271Q51783585-CDC7F3B1-CD18-4CA0-AA38-95E147100B14Q54964676-7A1A9240-261E-402C-AFAE-CB4148DCCF56Q58705762-B3ACF4C5-1CB1-455C-8510-7C4209ACF0C0
P2860
Eliminating epidemic Group A meningococcal meningitis in Africa through a new vaccine.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Eliminating epidemic Group A meningococcal meningitis in Africa through a new vaccine.
@ast
Eliminating epidemic Group A meningococcal meningitis in Africa through a new vaccine.
@en
Eliminating epidemic Group A meningococcal meningitis in Africa through a new vaccine.
@nl
type
label
Eliminating epidemic Group A meningococcal meningitis in Africa through a new vaccine.
@ast
Eliminating epidemic Group A meningococcal meningitis in Africa through a new vaccine.
@en
Eliminating epidemic Group A meningococcal meningitis in Africa through a new vaccine.
@nl
prefLabel
Eliminating epidemic Group A meningococcal meningitis in Africa through a new vaccine.
@ast
Eliminating epidemic Group A meningococcal meningitis in Africa through a new vaccine.
@en
Eliminating epidemic Group A meningococcal meningitis in Africa through a new vaccine.
@nl
P1433
P1476
Eliminating epidemic Group A meningococcal meningitis in Africa through a new vaccine.
@en
P2093
F Marc LaForce
Jean-Marie Okwo-Bele
P304
P356
10.1377/HLTHAFF.2011.0328
P407
P577
2011-06-01T00:00:00Z